Pharma stocks fall as Nifty Pharma drops 3%. Sun Pharma, Cipla slide amid US tariff fears and export risk concerns.
The current confusion is mostly between the classification of mid and small cap.
Two of the Big Whale Ashish Kacholia’s biggest holdings are strong contenders for the Watchlist 2026, with their stock prices…
Even as Nifty drifted flat, select midcaps stole the spotlight. SPARC soared, Wockhardt climbed, and Bajaj Housing Finance plunged after…
Seasonality suggests November softness and December strength, yet select Pharma counters consistently outperform. Three stocks offering the favourable risk-reward from…
Here are a list of stocks that saw a complete turnaround in performance for the September 2025 quarter.
While foreign investors have been reducing their exposure to Indian pharma, some leading domestic institutional investors (DIIs) are doing exactly…
Currently, Glenmark’s portfolio consists of 175 products authorized for distribution in the U.S. marketplace and 48 ANDAs pending approval with…
According to a statement, the collaboration between Wockhardt UK and Serum Life Sciences UK Ltd will help create a considerable…
Although it can not be established if this investment into Wockhardt is Rakesh Jhunjhunwala’s initial purchase of the firm’s stocks,…
Wockhardt in a BSE filing said that the manufacturing will be undertaken at CP Pharmaceuticals, a subsidiary of Wockhardt based…
Amtek Auto Shares ended 5.63 per cent down at Rs 27.65 after the company reported net loss of Rs 132.15…
According to the company, half of the issues will be resolved in next fortnight The nine observations received by Wockhardt…
The facility, which produces various products including ointments, capsules and tablets, currently caters to the UK and Ireland markets.
The USFDA has made nine ‘observations’ highlighting violations of its norms at homegrown drug maker Wockhardt’s new facility at Shendra…
Wockhardt shares fell as much as 12.69 per cent intraday on Friday on reports the company has received a notice…
WCK 5222 is a new class of antibiotic for gram negative terrain for complicated urinary tract infections and HABP/ VABP…
Drug maker Wockhardt has received qualified disease product (QIDP) status from US health regulator for a new antibiotic.